Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies (14.1)]. meloxicam tablet are indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies (14.1)]. meloxicam tablets are contraindicated in patients with known hypersensitivity (e.g. anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.13)]. meloxicam tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions (5.1)]. there are

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mi

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - nabumetone (unii: lw0tiw155z) (nabumetone - unii:lw0tiw155z) - nabumetone 500 mg - carefully consider the potential benefits and risks of nabumetone and other treatment options before deciding to use nabumetone. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. nabumetone tablets are contraindicated in patients with known hypersensitivity to nabumetone or its excipients. nabumetone should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings , anaphylactoid reactions , and precautions , preexisting asthma ). nabumetone tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 15 mg - meloxicam tablets, usp is indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies ( 14.1) ]. meloxicam tablets, usp is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies ( 14.1) ]. meloxicam tablets, usp is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age and older [ see clinical studies ( 14.2) ]. meloxicam is contraindicated in patients with known hypersensitivity (e.g., anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [ see warnings

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. ibuprofen tablets are indicated for relief of mild to moderate pain. ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-lik

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [ see warnings and precautions (5) ] celecoxib is indicated for relief of the signs and symptoms of oa [ see clinical studies (14.1) ] celecoxib is indicated for relief of the signs and symptoms of ra [ see clinical studies (14.2) ] celecoxib is indicated for relief of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] celecoxib is indicated for the relief of signs and symptoms of as [ see clinical studies (14.4) ] celecoxib is indicated for the management of ap in adults [ see clinical studies (14.5) ] celecoxib is indicated for the treatment of pd [

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 275 mg - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen or naproxen sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen as naproxen tablets or naproxen sodium tablets are indicated: naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen as naproxen tablets and naproxen sodium tablets are also indicated: naproxen and naproxen sodium are contraindicated in patients with known hypersensitivity to naproxen and naproxen sodium. naproxen and naproxen sodium should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reaction

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 550 mg - carefully consider the potential benefits and risks of naproxen sodium tablets and other treatment options before deciding to use naproxen sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen sodium tablets are indicated:       for the relief of the signs and symptoms of rheumatoid arthritis       for the relief of the signs and symptoms of osteoarthritis       for the relief of the signs and symptoms of ankylosing spondylitis        for the relief of the signs and symptoms of juvenile arthritis naproxen sodium tablets are also indicated: - for relief of the signs and symptoms of tendonitis - for relief of the signs and symptoms of bursitis - for relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary dysmenorrhea  naproxen sodium is contraindicated in patients with known hypers

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administration). naproxen delayed-release tablets are contraindicated in patients with known hypersensitivity to naproxen. naproxen delayed

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

blenheim pharmacal, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [ see warnings and precautions (5) ] celecoxib is indicated for relief of the signs and symptoms of oa [ see clinical studies (14.1) ] celecoxib is indicated for relief of the signs and symptoms of ra [ see clinical studies (14.2) ] celecoxib is indicated for relief of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] celecoxib is indicated for the relief of signs and symptoms of as [ see clinical studies (14.4) ] celecoxib is indicated for the management of ap in adults [ see clinical studies (14.5) ] celecoxib is indicated for the treatment of pd [